Healthcare Services

Chronic Pruritus Therapeutics Market Growth Expected to Reach $15.33 Billion by 2030 with 7% CAGR

March 31, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Chronic Pruritus Therapeutics Market During The Forecast Period 2026–2030?

The market for chronic pruritus therapeutics has experienced robust expansion over recent years. Projections indicate its size will increase from $10.91 billion in 2025 to $11.7 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 7.2%. This historical growth is linked to factors such as the rising incidence of chronic skin conditions, expanded application of topical corticosteroids, enhanced diagnostic clarity for pruritus etiologies, an uptick in consultations with dermatology specialists, and broader access to antihistamine treatments.

The chronic pruritus therapeutics market is projected to experience robust expansion in the coming years, set to reach a valuation of $15.33 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. This anticipated growth is driven by factors such as a rise in biologic drug approvals, increased investment in dermatology research pipelines, a heightened focus on immune-mediated itch mechanisms, broadening access to online pharmacies, and growing patient demand for enduring relief solutions. Key developments expected during this period involve a greater uptake of targeted biologic therapies, an intensifying focus on customized pruritus treatment strategies, the ongoing creation of innovative anti-itch molecules, the proliferation of combination therapy protocols, and a stronger emphasis on managing symptoms over the long term.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp

Which Major Factors Are Driving The Expansion Of The Chronic Pruritus Therapeutics Market?

The increase in healthcare spending is expected to drive the growth of the chronic pruritus therapeutics market in the coming years. Healthcare expenditure refers to the total amount spent by individuals, organizations, and governments on the prevention, treatment, and management of health conditions. This spending is rising due to advancements in medical technology, as new diagnostic methods, treatments, and innovative therapies often come with higher costs, contributing to overall healthcare expenses. Higher healthcare expenditure supports the chronic pruritus therapeutics market by improving access to dermatological care, encouraging the use of advanced treatments, and promoting investment in innovative solutions. For example, in December 2024, the Centers for Medicare & Medicaid Services reported that U.S. healthcare spending grew by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. Therefore, increasing healthcare expenditure is fueling the growth of the chronic pruritus therapeutics market.

What Market Segments Are Evaluated Within The Chronic Pruritus Therapeutics Market?

The chronic pruritus therapeutics market covered in this report is segmented –

1) By Product Type: Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, Other Product Types

2) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Other Disease Types

3) By Distribution Channel: Hospital Pharmacies, Drug stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Corticosteroid: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids

2) By Antihistamine: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetic: Topical Local Anesthetics, Injectable Local Anesthetics

4) By Counterirritant: Menthol-Based Counterirritants, Camphor-Based Counterirritants

5) By Immunosuppressant: Systemic Immunosuppressants, Topical Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy, Pimecrolimus-Based Therapy

7) By Other Product Types: Biologic Therapies, Emerging Novel Therapies

What Trends Are Advancing Progress In The Chronic Pruritus Therapeutics Market?

Leading firms in the chronic pruritus therapeutics market are prioritizing the creation of novel formulations, including intravenous (IV) injections, to boost treatment effectiveness and offer quicker patient relief. IV injections manage pruritus by directly introducing medications, like antihistamines or corticosteroids, into the bloodstream, thereby rapidly easing itching and diminishing inflammation. For example, in September 2023, Cara Therapeutics Inc., a US-based therapeutics manufacturer, disclosed that its collaborator, Maruishi Pharmaceutical Co. Ltd., a Japan-based pharmaceutical firm, secured approval from Japan’s Ministry of Health, Labour and Welfare, a Japan-based government agency, for Korsuva IV injection syringe, designed to treat pruritus in hemodialysis patients. This endorsement stemmed from favorable Phase 3 clinical trial outcomes conducted by Maruishi in partnership with Kissei Pharmaceutical Co., Ltd. The therapy demonstrated notable enhancements in itching scores relative to a placebo and was well-received by patients. Furthermore, this approval activates a $1.5 million milestone payment to Cara Therapeutics, the creator of Korsuva, in accordance with their licensing pact with Maruishi.

Who Are The Top Market Participants Influencing The Chronic Pruritus Therapeutics Market?

Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Cipla Limited, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

Read the full chronic pruritus therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report

Which Region Currently Holds The Largest Share Of The Chronic Pruritus Therapeutics Market?

North America was the largest region in the chronic pruritus therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Chronic Pruritus Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21147&type=smp

Browse Through More Reports Similar to the Global Chronic Pruritus Therapeutics Market 2026, By The Business Research Company

Chronic Spontaneous Urticaria Global Market Report

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Veterinary Dermatology Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/veterinary-dermatology-drugs-global-market-report

Rheumatology Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795